Stock DTIL PRECISION BIOSCIENCES, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company Precision BioSciences, Inc.

Equities

DTIL

US74019P2074

Biotechnology & Medical Research

Real-time Estimate Cboe BZX
Other stock markets
 11:03:19 2024-05-31 am EDT 		5-day change 1st Jan Change
13.24 USD +3.24% Intraday chart for Precision BioSciences, Inc. +4.55% +21.64%
12:00am Certain Stock Options of Precision BioSciences, Inc. are subject to a Lock-Up Agreement Ending on 31-MAY-2024. CI
12:00am Certain Common Stock of Precision BioSciences, Inc. are subject to a Lock-Up Agreement Ending on 31-MAY-2024. CI

Business Summary

Precision BioSciences, Inc. is an advanced gene editing company dedicated to improving life (DTIL) with its proprietary ARCUS genome editing platform. Using ARCUS, the Company's pipeline consists of in vivo gene editing candidates designed to deliver cures for a range of genetic and infectious diseases. The ARCUS platform develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision. ARCUS particularly generates defined outcomes due to predominant repair using homology directed repair (HDR) as opposed to non-homologous end joining (NHEJ). The Company’s in vivo gene editing programs include PBGENE-HBV, PBGENE-PMM, PBGENE-NVS, PBGENE-DMD, PBGENE-LL2, PBGENE-LL3 and iECURE-OTC. PBGENE-HBV program is designed for the potential treatment of chronic hepatitis B virus (HBV). The Company is pursuing development of PBGENE-PMM as a potential opportunity for treatment of m.3243 associated primary mitochondrial myopathy (PMM).

Number of employees: 109

Sales per Business

USD in Million2022Weight2023Weight Delta
Gene Editing
100.0 %
25 100.0 % 49 100.0 % +94.15%

Sales per region

USD in Million2022Weight2023Weight Delta
United States
100.0 %
25 100.0 % 49 100.0 % +94.15%

Managers

Managers TitleAgeSince
Michael Amoroso CEO
 Chief Executive Officer 46 21-10-14
Jeff Smith FOU
 Founder - 06-01-25
John Kelly DFI
 Director of Finance/CFO 57 20-10-13
Sinu Bhandaru COO
 Chief Operating Officer - 17-07-31
Alan List CTO
 Chief Tech/Sci/R&D Officer 69 21-04-25
Mei Burris AUD
 Comptroller/Controller/Auditor - 19-01-31
Juli Blanche HRO
 Human Resources Officer - 22-05-22
Cindy Atwell PRN
 Corporate Officer/Principal - 18-12-31
Dario Scimeca LAW
 General Counsel 49 19-06-11
Neil Leatherbury PRN
 Corporate Officer/Principal - 16-12-31

Members of the board

Members of the board TitleAgeSince
Kevin Buehler CHM
 Chairman 66 19-11-07
Geno Germano BRD
 Director/Board Member 63 20-03-09
Samuel Wadsworth BRD
 Director/Board Member 75 21-11-05
Melinda Brown BRD
 Director/Board Member 67 22-05-30
Michael Amoroso CEO
 Chief Executive Officer 46 21-10-14
Stanley Frankel BRD
 Director/Board Member 65 21-04-11
Shari Lisa Piré BRD
 Director/Board Member 59 21-11-05

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 6,952,613 6,300,603 ( 90.62 %) 27,015 ( 0.3886 %) 90.62 %

Shareholders

NameEquities%Valuation
Tang Capital Management LLC
8.524 %
589,569 8.524 % 6 M $
Janus Henderson Investors US LLC
8.286 %
573,052 8.286 % 6 M $
Janus Henderson Investors US LLC
7.390 %
511,108 7.390 % 5 M $
Perceptive Advisors LLC
7.229 %
500,000 7.229 % 5 M $
Perceptive Advisors LLC
6.947 %
480,483 6.947 % 5 M $
NOVARTIS AG
5.980 %
413,581 5.980 % 4 M $
Aquilo Capital Management LLC
5.573 %
385,440 5.573 % 4 M $
Aquilo Capital Management LLC
5.573 %
385,440 5.573 % 4 M $
Vanguard Group, Inc. (Subfiler)
3.771 %
260,831 3.771 % 3 M $
Alyeska Investment Group LP
3.615 %
250,000 3.615 % 2 M $

Company contact information

Precision BioSciences, Inc.

Dibrell Building 302 East Pettigrew Street

27701, Durham

+919 314 5512

http://www.precisionbiosciences.com
address Precision BioSciences, Inc.(DTIL)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Other Biotechnology & Medical Research

Ratings for Precision BioSciences, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
12.82 USD
Average target price
33 USD
Spread / Average Target
+157.41%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
PRECISION BIOSCIENCES, INC. Stock Precision BioSciences, Inc.
+21.64% 88.79M
MODERNA, INC. Stock Moderna, Inc.
+54.23% 58.06B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-5.80% 40.53B
LONZA GROUP AG Stock Lonza Group AG
+37.32% 38.99B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+13.34% 26.7B
CELLTRION, INC. Stock Celltrion, Inc.
-12.01% 26.56B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-21.38% 18.98B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+0.82% 12.17B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+23.31% 12B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+26.62% 11.92B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. DTIL Stock
  4. Company Precision BioSciences, Inc.